Where does Eolas Therapeutics, Inc rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Eolas Therapeutics, Inc ranks #35,211 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Eolas Therapeutics, Inc hold?

Eolas Therapeutics, Inc holds 7 US utility patents granted between 2016 and 2024, spanning 3 technology areas.

What is Eolas Therapeutics, Inc's Innovation Score?

Eolas Therapeutics, Inc has an Innovation Score of 33.3 out of 100 (44th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Eolas Therapeutics, Inc focus on?

Eolas Therapeutics, Inc's top technology area is C07D (Heterocyclic Compounds) with 7 patents, ranking #1,096 of 3,165 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

Is Eolas Therapeutics, Inc's patent grant rate increasing or decreasing?

Eolas Therapeutics, Inc's recent grant velocity is -25% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Eolas Therapeutics, Inc's patents?

Eolas Therapeutics, Inc's patents average 22.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Eolas Therapeutics, Inc patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Eolas Therapeutics, Inc

USPTO PatentsView assignee record - 7 granted patents across 3 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Eolas ranks #35,211 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 3 technology areas.

#35,211
of 49,997 US assignees by volume: 44th percentile
by Innovation Score (33.3/100): 22.1
avg claims per patent: -25%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R35211 · US Corporation #35,211 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 7 grants
MID-PACK #35,211/49,997
PHOTO-FINISH Energy Control
CPC-NARROW C07D · 3 areas
INNOV-THIN 33.3/100
CLAIMS-DENSE 22.1 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -25% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Energy Control Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Eolas’s 33.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (22%) Velocity 6.7 pts (20%) Breadth 6.1 pts (18%) Claim depth 13.3 pts (40%)

Qualcomm Incorporated · highest

85
Eolas Therapeutics · this assignee

33
3D Lighting… · lowest

7

What this shows Eolas's Innovation Score is 33.3/100 (44th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Eolas?

Each dot is one of Eolas’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Eolas’s own 22.1 claims/patent is ABOVE the 14.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Eolas vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Eolas's grants concentrate

Eolas Therapeutics, Inc is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2018. By volume, Eolas sits between Energy Control Limited and Epilog Imaging Systems, Inc..

Eolas's three-year grant acceleration

Eolas Therapeutics, Inc shows 2 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Energy Control

7
Enpress

7
Enyo Pharma

7
Enzymaster (Ningb…

7
EON Reality

7
Eospace

7
Epileds

7
Epilog Imaging Sy…

7
Eolas Therapeutics ◀

7

What this shows Eolas holds 7 patents at rank #35,150, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Eolas

By rank, the assignees closest to #35,150 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Eolas's primary technology class.

Eolas's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 44th percentile higher than 44% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Eolas Therapeutics, Inc patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	28.6%
2018	1	14.3%
2019	1	14.3%
2021	1	14.3%
2022	1	14.3%
2024	1	14.3%

Which technologies does Eolas Therapeutics, Inc patent most?

C07D - Heterocyclic Compounds 7

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Eolas Therapeutics, Inc's patent record in context - here's where to go next.

Eolas Therapeutics, Inc's lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #35,211 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Eolas Therapeutics, Inc against Energy Control Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 33.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.